Breaking News

Sartorius Opens New Competence Center in Freiburg, Germany

Reaffirms its strategic focus on manufacturing essential components such as cytokines and growth factors used in novel cell and gene therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Sartorius has opened a new competence center in Freiburg, Germany, dedicated to the development and production of quality-critical materials for the cell and gene therapy market.

With an investment of more than 140 million euros ($152.5 million), Sartorius is reaffirming its strategic focus on manufacturing essential components such as cytokines and growth factors used in novel cell and gene therapies.

“Cell and gene therapies offer patients hope for curing diseases that were previously considered untreatable. Cytokines, growth factors, and cell culture media are essential for the development and manufacture of these innovative therapies. As a key site in our global network for these critical materials, Freiburg serves a dynamic market with high requirements for speed, scalability, and process reliability. By significantly expanding our capacities, we can respond much more flexibly to demand from our biopharma customers and support them even better in bringing cell and gene therapies to patients faster and more efficiently,” said René Fáber, Head of the Bioprocess Solutions Division and member of the Sartorius Executive Board.

The site covers approximately 18,000 square meters.

According to the company, “state-of-the-art” production, laboratory, and office spaces have already been created in the Haid industrial park. The site covers approximately 18,000 square meters and can accommodate up to 180 employees. The new facility meets the highest GMP quality standards. In addition, it operates entirely without fossil fuels due to innovative building technology: geothermal energy provides heating, well water provides cooling, and solar panels generate electricity. For this focus on sustainability, the site has already been recognized with a Gold pre-certification by the German Sustainable Building Council.

The development of the site is part of a long-term investment program aimed at expanding Sartorius’s global research and manufacturing network. The objective is to prepare the company for further organic growth, strengthen its resilience, and continue to ensure high delivery reliability and consistent product quality across all locations.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters